Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zIFV
- Development stage
- Preclinical
- Lead developer
- VaxDome
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
zIFV is an antigen-agnostic, intranasally delivered antiviral-vaccine hybrid candidate developed by VaxDome. It is designed to provide broad, mutation-agnostic protection against diverse known and unknown viral pathogens, such as influenza, as well as therapeutic efficacy against lung cancer. The platform works by rapidly transforming a selected influenza virus strain into a safe, non-invasive hybrid that mobilizes rapid innate and adaptive immune responses without inducing harmful systemic inflammation. In oncology, zIFV has demonstrated potential to arrest lung cancer in situ by rapidly generating tertiary lymphoid structures within tumors and mitigating lymphopenia.
Beyond the preview
Go deeper on zIFV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zIFV.